Full-Time

Vice President

Patient Operations

Confirmed live in the last 24 hours

Beam Therapeutics

Beam Therapeutics

501-1,000 employees

Develops precision genetic medicines using base editing

Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Category
Genomics
Public Health
Biology & Biotech
Requirements
  • BS/BA in a relevant academic field; MBA, MD, PhD, or other graduate degree strongly preferred with 20+ years experience within the pharma/biotech/biopharma space in roles of progressively increasing responsibility.
  • Experience in gene and/or cell therapy strongly desired, particularly in autologous cell therapy.
  • Sophisticated understanding of the operational complexity and evolving scientific, clinical, regulatory, competitive, and economic trends in the cell / gene therapy industry, and able to adapt operational strategies accordingly.
  • Proven track record in cross-functional leadership role or other cross-disciplinary background with successful team leadership experience required.
  • Exceptional interpersonal skills and collaborative nature with strong ability to influence, motivate, inspire, encourage and develop others.
  • Driven by patient needs and comfortable operating in a highly complex and technical environment while dealing with ambiguity.
  • Experience with U.S. commercialization preferred.
  • Experience in both large and small company environments a plus.
Responsibilities
  • Define strategy for Patient Operations, including patient scheduling rules, manufacturing slot allocation, and exception management
  • Partner with Manufacturing, Supply Chain, Quality, Regulatory, IT and others to ensure scalable processes for patient scheduling and apheresis operations that meet both Beam’s business needs and ensure a positive patient and provider treatment experience
  • Provide strategic and operational leadership to the implementation of a cell therapy orchestration platform and integration into other systems to enable functions such as patient registration and scheduling, chain of identity / chain of custody (COI/COC) traceability, order management, inbound and outbound cell logistics etc.
  • Define organizational needs to onboard and support apheresis operations at treatment centers
  • Build and manage teams to execute patient scheduling and apheresis operations

Beam Therapeutics develops precision genetic medicines using a technique called base editing, which allows for precise modifications to the genetic code to potentially correct mutations that lead to serious diseases. Their primary focus is on treating genetic disorders, such as sickle cell disease, with the aim of providing lifelong cures rather than temporary solutions. The company invests significantly in research and development to create new therapies and generates revenue through partnerships, licensing agreements, and future commercialization of their treatments. Beam Therapeutics distinguishes itself from competitors by its commitment to rigorous scientific development and a values-driven approach, emphasizing the importance of its expert team. The ultimate goal of the company is to advance genetic medicine to offer lasting cures for patients.

Company Stage

IPO

Total Funding

$215.9M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

2%

1 year growth

-2%

2 year growth

-6%
Simplify Jobs

Simplify's Take

What believers are saying

  • Beam Therapeutics' innovative base editing technology has the potential to revolutionize the treatment of genetic disorders, offering hope for lifelong cures.
  • The company's strong pipeline, including early-stage studies for sickle cell disease, positions it well for future growth and breakthroughs.
  • Significant investments and partnerships, like the recent $250 million deal with Eli Lilly, enhance Beam's financial stability and research capabilities.

What critics are saying

  • The recent retirement of CFO Terry-Ann Burrell and the layoff of 20% of staff could lead to operational disruptions and affect company morale.
  • Beam's focus on early-stage studies means that its treatments are still years away from commercialization, posing a risk to short-term revenue generation.

What makes Beam Therapeutics unique

  • Beam Therapeutics leverages base editing technology, which allows for precise genetic modifications, setting it apart from traditional gene-editing methods like CRISPR.
  • The company's focus on developing lifelong cures for genetic disorders, rather than temporary treatments, distinguishes it in the biotechnology sector.
  • Beam's strategic partnerships and licensing agreements, such as the $250 million deal with Eli Lilly, provide significant financial backing and collaborative opportunities.

Help us improve and share your feedback! Did you find this helpful?